Myomo Becomes the First Company to List on the New NYSE MKT as Result of Filing Title IV, Reg A+ Mini-IPO Offering with the SEC

With the powered brace, a paralyzed individual can perform activities of daily living including feeding themselves, carrying objects and doing household tasks, and many are able to return to work

By Robert Hoskins, Crowdfunding PR

Cambridge, Massachusetts – Myomo, Inc. (NYSE MKT: MYO) announced the launch of its next-generation MyoPro® myoelectric arm orthosis (powered brace), the only lightweight wearable device that can restore function in the paralyzed or weakened arms and hands of individuals who have suffered a stroke, spinal cord or nerve injury, or other neuromuscular disability. With the orthosis, a paralyzed individual can perform activities of daily living including feeding themselves, carrying objects and doing household tasks, and many are able to return to work.

Even if you haven’t moved your hand and arm in years due to a neuromuscular injury or disease, it is possible that the MyoPro myoelectric orthosis may be able to help you use your arm and hand again

The product is currently being shipped to customers nationwide after a successful Title IV, Reg + crowdfunding campaign campaign conducted on Banq’s fundraising platform.

Also Read: Top 100 Equity Crowdfunding Sites in the United States

Following the intentions of the SEC, which enacted the formal rules passed by the Jumpstart Our Business Startups (JOBS) Act passed under the Obama administration in 2012, Myomo utilized Title IV, Regulation A+, also referred to as a mini Initial Public Offering (IPO), to raise a minimum target of $15 million.

Myomo is the first company to complete a mini-IPO under Reg A+. In accordance with a portion Reg A+ rules, Myomo stated its intent to list its shares on the NYSE MKT exchange soon after the Reg A+ offering closed and will be trading under the symbol “MYO.”

On opening day, NYSE MYO raised approximately $5 million by selling 665,498 shares of its common stock to the public at $7.50 per share. Share price crested on June 19th at $19.31 and is actively trading.

MyoPro 2 extends the capabilities of the previous device with significant enhancements, including interchangeable, extended-life rechargeable batteries for continuous daily use. Additional enhancements include an upgraded user interface, improved sensors and improved harness and finger grasp orthosis for more reliable and comfortable long-term wear.

MyoPro 2 is available in three models to match patient-specific needs:

• Motion E: powered elbow with static rigid wrist support;
• Motion W: powered elbow and a multi-articulating wrist with flexion/extension and supination/pronation; and
• Motion G: powered elbow, a multi-articulating wrist and a powered 3-jaw-chuck grasp.

“MyoPro 2 is the result of collaboration between our users, clinical partners and engineering team to help patients restore their activities of daily living,” said Paul R. Gudonis, Chairman and CEO of Myomo. “Early in our rollout, feedback from patients, physicians and the orthotics and prosthetics community has been very positive. We look forward to addressing the large unmet need in upper limb paralysis as we continue to bring MyoPro 2 to a larger market.”

Myomo, Inc. is a commercial stage medical robotics Company that offers expanded mobility for those suffering from neurological disorders and upper limb paralysis. Based on patented technology developed at MIT and the Company, Myomo develops and markets the MyoPro® product line of lightweight, non-invasive, powered arm braces to restore function in the paralyzed or weakened arms and hands of individuals that have suffered a stroke, spinal cord or nerve injury such as brachial plexus injury, or other neuromuscular disability such as amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS).

It is provided through clinical relationships with VA medical centers, leading rehabilitation hospitals, and Orthotics and Prosthetics (“O&P”) practices. Several hundred have been successfully used by patients. It is the only device that, sensing a patient’s own neurological signals through non-invasive sensors on the arm, can restore their ability to use their arms and hands so that they can return to work, live independently and reduce their cost of care.

# # #

Robert Hoskins
(512) 627-6622
@Crowdfunding_PR

---

Mr. Robert Hoskins is a seasoned marketing veteran with a proven track record of helping entrepreneurs, startups, small businesses as well as Fortune 500 corporations launch successful marketing communications campaigns to gain market traction for a wide variety of products and services.

On a regular basis, Mr. Hoskins consults with crowdfunding campaign managers as well as crowdfunding sites, portals and platforms to deliver successful crowdfunding marketing campaigns.

Google search “Robert Hoskins Crowdfunding” to see why Mr. Hoskins runs one of the industry’s foremost crowdfunding PR, social media and marketing agencies that has amassed a huge social media following and is dedicated to supporting a wide variety of donation, rewards and equity crowdfunding campaigns.

Advertisement